RTP Mobile Logo
Submitted by web@researchtop... on Thu, 09/19/2019 - 11:50

Interview with Professor Dr Stephan Stilgenbauer

Track 1: Updated International Workshop on Chronic Lymphocytic Leukemia guidelines for diagnosis, indications for treatment, response assessment and management of chronic lymphocytic leukemia (CLL)
Track 2: Genetic abnormalities in CLL; effects of p53 mutations and 17p deletion on prognosis and therapy
Track 3: Design and eligibility for the Phase III CLL14 trial of venetoclax/obinutuzumab versus chlorambucil/obinutuzumab for patients with previously untreated CLL and coexisting medical conditions
Track 4: Recent data from the Phase III iLLUMINATE, Alliance A041202 and ECOG-E1912 trials comparing ibrutinib-based regimens to chemoimmunotherapy as first-line treatment for patients with CLL
Track 5: Results from the CLL14 trial comparing venetoclax to chlorambucil as an addition to fixed-duration obinutuzumab therapy for CLL
Track 6: Management of disease relapse on the CLL14 trial; role of minimal residual disease (MRD) assessment in therapeutic decision-making
Track 7: Dosing and administration of the recently FDA-approved first-line regimen of venetoclax and obinutuzumab; mitigation of risk for tumor lysis syndrome
Track 8: Mechanism of action of venetoclax; role of renal function in the decision to administer this agent
Track 9: Emerging data with the combination of ibrutinib or venetoclax with anti-CD20 antibodies
Track 10: Del(17p) and/or p53 mutation status and the selection of therapy for patients with CLL
Track 11: Role of bendamustine/rituximab in the management of CLL
Track 12: Perspective on the efficacy of venetoclax/obinutuzumab versus ibrutinib as first-line therapy for patients with CLL
Track 13: Case: A man in his mid-60s with del(17p) CLL and no IGHV mutation experiences a dramatic response to first-line ibrutinib
Track 14: Prolonged lymphocytosis during ibrutinib therapy
Track 15: Clonal evolution in CLL; importance of monitoring for del(17p) and p53 mutations before treatment initiation
Track 16: Sequencing of ibrutinib and venetoclax for patients with CLL; tolerability and quality of life with ibrutinib versus venetoclax
Track 17: Management of arthralgias associated with Bruton tyrosine kinase (BTK) inhibitors
Track 18: Case: A woman in her mid-70s with del(13q) CLL and no IGHV mutation receives acalabrutinib after experiencing disease progression on multiple lines of therapy, including ibrutinib
Track 19: BTK inhibitor-associated headaches and atrial fibrillation
Track 20: Efficacy of ibrutinib versus acalabrutinib; ongoing Phase III ACE-CL-006 study comparing acalabrutinib to ibrutinib for previously treated, high-risk CLL
Track 21: Case: A man in his late 70s with del(11q) CLL and no IGHV mutation attains a complete response and MRD-negative status with venetoclax and obinutuzumab on the Phase III CLL14 trial
Track 22: Side effects of venetoclax/obinutuzumab
Track 23: Case: A man in his early 70s with hairy cell leukemia (HCL) and a BRAF mutation experiences disease progression after receiving vemurafenib as second-line therapy
Track 24: Activity and tolerability of the recently FDA-approved antibody-drug conjugate moxetumomab pasudotox-tdfk in patients with relapsed/refractory HCL
Track 25: Novel approaches under investigation for HCL
Track 26: Case: A woman in her late 50s develops Richter’s transformation (RT) from CLL to diffuse large B-cell lymphoma (DLBCL) after receiving ibrutinib as second-line therapy
Track 27: Pathogenesis and frequency of RT in patients with relapsed/refractory CLL
Track 28: Comparison of the biology of Richter’s transformed versus de novo DLBCL; novel therapies under investigation for RT

Interview with Jennifer Woyach, MD

Track 1: Recent data and evolution of the front-line treatment paradigm for patients with CLL
Track 2: Evaluation of MRD and implications for therapy
Track 3: Efficacy and tolerability of first-line regimens for CLL
Track 4: Perspective on the role of chemoimmunotherapy for patients with CLL
Track 5: Case: A woman in her mid-70s experiences a dramatic response after receiving ibrutinib as first-line therapy for CLL
Track 6: Bleeding and arthralgias associated with ibrutinib
Track 7: Rates of discontinuation and the role of dose reduction to mitigate side effects in patients receiving ibrutinib
Track 8: Incidence and management of opportunistic infections during ibrutinib treatment
Track 9: Role of chimeric antigen receptor (CAR) T-cell therapy in CLL; effect of ibrutinib on CAR T-cell generation and efficacy
Track 10: Case: A man in his late 60s with CLL receives acalabrutinib on a clinical trial after developing atrial fibrillation on ibrutinib therapy
Track 11: Therapeutic approach for patients who develop resistance to BTK inhibitors
Track 12: Understanding the C481S mutation as a mechanism of resistance to ibrutinib and acalabrutinib
Track 13: Targeting the C481S mutation to overcome resistance to BTK inhibitors
Track 14: Case: A woman in her mid-60s with del(17p) CLL and no IGHV mutation receives venetoclax after disease progression on multiple lines of therapy
Track 15: Prophylactic measures to prevent venetoclax-associated tumor lysis syndrome
Track 16: Emerging data with the combination of ibrutinib and venetoclax for CLL
Track 17: Activity and tolerability of PI3 kinase inhibitors for patients with CLL
Track 18: Acalabrutinib with obinutuzumab for treatment-naïve and relapsed/refractory CLL
Track 19: Incidence and spectrum of second cancers among patients with CLL receiving BTK inhibitors
Track 20: Case: A man in his early 70s develops RT to DLBCL after receiving ibrutinib as first-line therapy for CLL
Track 21: Prognosis and management of RT
Track 22: Role of immune checkpoint inhibitors and CAR T-cell therapy in the management of RT
Track 23: Ongoing Phase III EA9161 and Alliance A041702 studies evaluating the addition of venetoclax to ibrutinib with obinutuzumab for patients with CLL
 
FACULTY
 
Professor Dr Stephan Stilgenbauer
Ulm University
Ulm, Germany
Saarland University
Homburg, Germany
 
Jennifer Woyach, MD
Associate Professor
Division of Hematology
Department of Internal Medicine
The Ohio State University
Comprehensive Cancer Center
Columbus, Ohio
 
EDITOR
 
Neil Love, MD
Research To Practice
Miami, Florida